At the same time, transwell assay showed that tumor invasiveness was enhanced after overexpression of MDM2, and the addition of Rosiglitazone significantly reduced the ability of the tumor cell migration (Figure S16F, Supporting Information). The gene discussed is MDM2; the disease is neoplasm.